Sign in to view content

Phase 1/2 Clinical Trial of Intravitreal 4D-125 AAV Gene Therapy in Patients with Advanced XLRP: Interim Safety & Preliminary Activity

Cagri G Besirli, MD, PhD, FASRS

Video
Published 2021

Related

A Multicenter Post-Authorization Safety Study of Patients Treated With Voretigene Neparvovec-rzyl Gene Therapy in the United States: Interim Analysis at 3 Years
Aaron Nagiel, MD, PhD
Annual Meeting Talks
2024
Episode 150: Ophthalmic Genetics with Dr. Mark Pennesi
Jayanth Sridhar, MD
Member Podcasts
2018
Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 8 Years and 9 Years
Stephen R. Russell, MD
Annual Meeting Talks
2024

Category: Hereditary Retinal Disease & Genetics

See more